A panel of tumor-specific markers (GLUT1, EGFR, HER2, IGF1-R, MET, and CAIX) was in the present study able to 'detect' 45.5% of all cancers and 55.6% of ductal cancers. The gene discussed is ERBB2; the disease is cancer.